ArticleInfectious diseases and therapy2026
Interim Effectiveness of 2025-2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States.
Nevena Vicic et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.